Abstract：
UNASSIGNED: Chronic lower back pain is a leading cause of disability and healthcare spending worldwide. Discogenic pain, pain originating from the intervertebral disk, is a common etiology of chronic lower back pain. Currently, accepted treatments for chronic discogenic pain focus only on the management of symptoms, such as pain. There are no approved treatments that stop or reverse degenerating intervertebral discs. Biologic therapies promoting disc regeneration have been developed to expand treatment options. VIADISC™ NP, is a viable disc allograft supplementation that, in a recent trial, demonstrated a significant reduction in pain and increased function in patients suffering from symptomatic degenerative disc disease.
UNASSIGNED: This manuscript summarizes the epidemiology and etiology of low back pain, the pathophysiology of degenerative disc disease, current treatments, and a need for newer therapies. The rationale behind intradiscal biologics for the treatment of symptomatic degenerative disc disease is also discussed.
UNASSIGNED: Characterization of the biology leading to disc degeneration has allowed for the development of intradiscal biologics. They may soon be capable of preventing and reversing disc degeneration. Clinical trials have shown promise, but further research into efficacy and safety is needed before these therapies are widely employed.
UNASSIGNED: This manuscript summarizes the epidemiology and etiology of low back pain, the pathophysiology of degenerative disc disease, current treatments, and a need for newer therapies. The rationale behind intradiscal biologics for the treatment of symptomatic degenerative disc disease is also discussed.
UNASSIGNED: Characterization of the biology leading to disc degeneration has allowed for the development of intradiscal biologics. They may soon be capable of preventing and reversing disc degeneration. Clinical trials have shown promise, but further research into efficacy and safety is needed before these therapies are widely employed.
摘要：
慢性腰痛是全球残疾和医疗保健支出的主要原因。椎间盘源性疼痛，源自椎间盘的疼痛，是慢性下背痛的常见病因。目前,接受的慢性椎间盘源性疼痛的治疗仅集中在症状的管理，如疼痛。没有批准的治疗方法可以阻止或逆转椎间盘的退化。已经开发了促进椎间盘再生的生物疗法以扩展治疗选择。VIADISC™NP,是一种可行的椎间盘同种异体移植补充剂，在最近的一次审判中,在患有症状性椎间盘退行性疾病的患者中，疼痛显着减轻，功能增强。
■这篇手稿总结了下腰痛的流行病学和病因学，椎间盘退行性疾病的病理生理学，目前的治疗方法，需要更新的疗法。还讨论了椎间盘内生物制剂治疗症状性椎间盘退行性疾病的基本原理。
■导致椎间盘退变的生物学特征允许椎间盘内生物制剂的发展。它们可能很快就能够预防和逆转椎间盘退变。临床试验显示出了希望，但在这些疗法被广泛应用之前，还需要进一步研究疗效和安全性。
■这篇手稿总结了下腰痛的流行病学和病因学，椎间盘退行性疾病的病理生理学，目前的治疗方法，需要更新的疗法。还讨论了椎间盘内生物制剂治疗症状性椎间盘退行性疾病的基本原理。
■导致椎间盘退变的生物学特征允许椎间盘内生物制剂的发展。它们可能很快就能够预防和逆转椎间盘退变。临床试验显示出了希望，但在这些疗法被广泛应用之前，还需要进一步研究疗效和安全性。
